Comparative Pharmacology
Head-to-head clinical analysis: SULFANILAMIDE versus SULFAPYRIDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFANILAMIDE versus SULFAPYRIDINE.
SULFANILAMIDE vs SULFAPYRIDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydropteroic acid, thereby inhibiting bacterial folic acid synthesis.
Sulfapyridine is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thereby nucleic acid production. It also has anti-inflammatory and immunomodulatory effects in dermatologic conditions through unknown mechanisms.
2-4 g orally initially, then 2-4 g every 4-6 hours, not to exceed 12 g/day; intravenous: 4-8 g/day in divided doses every 6-8 hours.
500 mg orally four times daily for initial treatment of dermatitis herpetiformis; maintenance dose 500 mg daily to 1.5 g daily in divided doses.
None Documented
None Documented
Clinical Note
moderateSulfanilamide + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sulfanilamide."
Clinical Note
moderateSulfanilamide + Atorvastatin
"The risk or severity of adverse effects can be increased when Sulfanilamide is combined with Atorvastatin."
Clinical Note
moderateSulfanilamide + Mecamylamine
"The risk or severity of adverse effects can be increased when Sulfanilamide is combined with Mecamylamine."
Clinical Note
moderateTerminal elimination half-life: 7-12 hours; prolonged in renal impairment (up to 24-48 hours).
Terminal elimination half-life: 6–10 hours (prolonged in renal impairment or slow acetylators); clinical context: requires dosing adjustment in renal insufficiency.
Primarily renal via glomerular filtration and tubular secretion; ~50-70% excreted unchanged in urine; biliary/fecal excretion minimal (<5%).
Renal: approximately 70–80% (30% as unchanged drug, remainder as metabolites, primarily N4-acetylsulfapyridine); biliary/fecal: minor (<5%).
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic
Sulfapyridine + Mecamylamine
"The risk or severity of adverse effects can be increased when Sulfapyridine is combined with Mecamylamine."